Drug Discovery World

DECEMBER 11, 2023

The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a possibly game-changing schizophrenia drug entering human trials.

Drugs 59

Drugs Trials Research 59

Drug Discovery World

MARCH 1, 2024

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative.

Drugs 52

Drugs Allergies FDA Approval Medicine 52

STAT News

AUGUST 11, 2022

We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry. Read the rest…

Gene Therapy 98

Gene Therapy Life Science Drugs Scientist 98

Drug Discovery World

DECEMBER 11, 2023

The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a possibly game-changing schizophrenia drug entering human trials.

Drugs 52

Drugs Trials Research 52

The Pharma Data

AUGUST 31, 2021

(NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. About Schizophrenia. Food and Drug Administration (FDA).

Drugs 52

Drugs Development Sales Clinical Development 52

BioTech 365

SEPTEMBER 5, 2021

DGAP-News: Newron Pharmaceuticals S.p.A. / Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia Evenamide has the potential to be … Continue reading → Key word(s): Study 06.09.2021 / 07:00 The issuer is solely responsible for the content of this announcement.

40

40

BioTech 365

MARCH 31, 2021

DGAP-News: Newron Pharmaceuticals S.p.A. / Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia Primary objective … Continue reading → Key word(s): Study results 01.04.2021 / 07:00 The issuer is solely responsible for the content of this announcement.

40

40

BioTech 365

JANUARY 20, 2021

DGAP-News: Newron Pharmaceuticals S.p.A. / Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients Final study data … Continue reading → Key word(s): Study 21.01.2021 / 07:02 The issuer is solely responsible for the content of this announcement.

40

40

Pharmaceutical Technology

DECEMBER 12, 2022

Regulatory decisions and clinical trial news. A few months after announcing positive results from one Phase III schizophrenia study in August, Karuna Therapeutics said it would initiate a Phase III program studying its drug KarXT (trospium chloride + xanomeline) as an adjunct therapy for schizophrenia.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

World of DTC Marketing

JUNE 5, 2021

Obesity is associated with neurodegenerative diseases (Alzheimer’s, Parkinson’s, and Huntington diseases) and neurodevelopmental diseases (autism disorder, schizophrenia, and fragile X syndrome).

Medicine 193

Medicine Gene Genetics Research 193

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration (FDA) Breakthrough Therapy and Fast Track Designations, is now in pivotal testing, and CTP-692 for schizophrenia is currently on track for topline data readout in the first quarter of 2021,” said Roger Tung, Ph.D., New CTP-543 Data Presented in Late-Breaking News Session at EADV 2020.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

Drug Discovery World

DECEMBER 26, 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Compound that can block cancer metastasis In DDW’s most-read news stoy of 2023, researchers from the University of Liverpool, UK, created a biomedical compound that has the potential to stop the spread of breast cancer.

Development 64

Development Clinical Trials Clinical Trials Drugs 64

pharmaphorum

AUGUST 5, 2022

The latest milestone payment has been triggered by FDA approval to start a phase 2 trial of the drug in schizophrenia, said Sosei Heptares this morning. News of the milestone comes just a few days after Sosei Heptares added to its portfolio of big-ticket partnership deals with a $1.2

Clinical Trials 52

Clinical Trials Clinical Trials Trials FDA Approval 52

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Drug Discovery World

DECEMBER 7, 2023

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. Overactive transmission of dopamine is connected to the positive, negative and cognitive symptoms of schizophrenia.

Trials 119

Trials Drugs Clinical Trials Clinical Trials 119

Drug Discovery World

APRIL 5, 2024

“Our goal at Neurosterix is to develop new medicines based on allosteric modulation that overcome the burdens of traditional drugs and provide patients with the potential to dramatically improve their lives.” Allosteric modulators bind to their target receptor outside of the active site, where the natural ligand and traditional drugs operate.

Life Science 52

Life Science Medicine Development Drugs 52

Drug Discovery World

FEBRUARY 29, 2024

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug application (NDA).

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Trials 52

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. ” The new data could accelerate partnering efforts of the drug this year.

Trials 102

Trials Drugs Sales Medicine 102

Drug Discovery World

JANUARY 8, 2024

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The post “Highly encouraging” results for treatment-resistant schizophrenia drug appeared first on Drug Discovery World (DDW).

Drugs 59

Drugs Medicine Trials Clinical Trials 59

Delveinsight

FEBRUARY 2, 2021

The shares of Viela Bio skyrocketed more than 52% in premarket trading after the news was broadcasted. Thus, the news of its acquisition does not surprise as a horde of pharma giants would be keeping a keen eye on its activities. Concert Pharmaceuticals Falls Flat After its Schizophrenia Drug Fails.

Drugs 40

Drugs Clinical Trials Clinical Trials Development 40

pharmaphorum

APRIL 20, 2022

Teva’s long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company’s long-acting formulation of schizophrenia drug risperidone. The post Teva’s long-acting schizophrenia drug rejected by FDA appeared first on.

Drugs 93

Drugs Marketing Sales Regulation 93

Delveinsight

DECEMBER 17, 2020

It also picks up CAD-9303, a schizophrenia treatment, and CAD-1883 that is in development for movement disorders. Under the agreement, Novartis will acquire the milestones and royalties for the depression asset, MIJ821, which is in testing phase 2 study.

Gene Therapy 96

Gene Therapy Gene DNA Genetics 96

XTalks

JANUARY 19, 2023

The US Food and Drug Administration (FDA) has approved Luye Pharma’s Rykindo (risperidone) for the treatment of schizophrenia and as a monotherapy or adjunctive therapy for the maintenance treatment of bipolar I disorder in adults. Both schizophrenia and bipolar disorder are severe mental disorders. percent and 0.64

FDA Approval 52

FDA Approval Marketing Drugs Clinical Trials 52

pharmaphorum

SEPTEMBER 1, 2021

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Janssen is trumpeting a new version of its Invega drug that could solve that problem. ” The post FDA clears J&J’s twice-yearly Invega for schizophrenia appeared first on.

FDA Approval 84

FDA Approval Sales Compliance Clinical Trials 84

Drug Discovery World

MARCH 20, 2023

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. The study is the first known work of its kind to investigate schizophrenia risk across diverse populations, particularly those of African ancestry.

Gene 52

Gene Research Genetics Gene Sequencing 52

Scienmag

JANUARY 26, 2022

New research has shown that over-activity in a specific area of the brain is linked to certain symptoms of Schizophrenia, opening up possibilities for the development of more targeted treatments.

Research 74

Research Development 74

Drug Discovery World

FEBRUARY 17, 2023

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.

Trials 52

Trials Research Drugs Clinical Trials 52

Scienmag

JANUARY 14, 2022

Scientists from Cardiff University have discovered new links between the breakdown in brain cell development and the risk of schizophrenia and other psychiatric disorders. Genetic risk factors are known to disrupt brain development in a number of these disorders, but little is known about which aspects of this process are affected.

Development 73

Development Genetics Scientist Research 73

Drug Discovery World

FEBRUARY 15, 2023

The company also has research collaborations with Merck, to identify novel targets for Alzheimer’s disease, and Takeda, focusing on new therapies for GI disorders. Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.

Trials 52

Trials Clinical Trials Clinical Trials Development 52

pharmaphorum

JANUARY 16, 2023

Rykindo has been approved for the treatment of schizophrenia and as monotherapy or adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults by the US regulator. ” The post Luye claims its first FDA approval, for bi-weekly schizophrenia drug appeared first on.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

pharmaphorum

DECEMBER 20, 2022

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will provide additional treatment options to those living with schizophrenia. Schizophrenia is one of the 15 leading causes of disability worldwide.

Behavioural Health 52

Behavioural Health Development Research 52

Scienmag

APRIL 28, 2022

Schizophrenia is a serious psychiatric disorder that starts in late adolescence or early adulthood and affects around 1 in 300 people worldwide, according to the World Health Organization. In a paper published April 8 in Nature, specific genes were identified that could play important roles in the psychiatric disorder.

Gene 59

Gene Research Genetics 59

Scienmag

JANUARY 11, 2022

(January 11, 2022) – In a breakthrough that holds significant promise for early diagnosis and better treatment of psychiatric illness, researchers have for the first time used neurons derived from human stem cells to predict the cardinal features of a psychiatric illness, such as psychosis and cognitive deficits in patients with schizophrenia.

Research 63

Research 63

Scienmag

DECEMBER 22, 2021

Genes code for proteins – the building blocks of life. The current definition of a gene only accounts for around 1.5% of our entire DNA Very little is known about the function of regions of DNA outside our genes – termed the ‘dark genome’ A Cambridge-led team recently discovered that proteins are produced by over […].

Genome 63

Genome Genomics DNA Gene 63

Scienmag

MARCH 15, 2022

Schizophrenia is a severe and disabling mental illness, which can lead to problems with work and relationships, being the victim of discrimination and violence, and early death. In low-income countries, such as Ethiopia, up to 90% of people with schizophrenia do not access any treatment.

59

59

pharmaphorum

DECEMBER 17, 2020

This includes CAD-9303, a NMDAr positive allosteric modulator that could be used to treat schizophrenia, and MIJ-821, a NMDAr negative allosteric modulator for depression that was licensed to Novartis in 2015. With the acquisition of Cambridge, Massachusetts-based Cadent, Novartis gains rights to a portfolio of neurology drugs.

Licensing 71

Licensing Licensing Genetics Drugs 71

pharmaphorum

APRIL 7, 2022

BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.

Drugs 52

Drugs Production Trials Marketing 52